Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001493152-23-015231 0001432078 XXXXXXXX LIVE 4 Common Stock, $0.0001 par value per share 04/10/2025 false 0001938046 56270V205 MANGOCEUTICALS, INC. 15110 DALLAS PKWY, SUITE 600 Dallas TX 75248 Jacob D. Cohen (214) 242-9619 15110 N. Dallas Parkway, Suite 600 Dallas TX 75248 0001432078 N Jacob D. Cohen a OO N X1 316666.00 605000.00 316666.00 605000.00 921666.00 N 11.0 IN (7)(9)(11) Includes 83,333 shares of common stock issuable upon exercise of options to purchase shares of common stock at an exercise price of $4.80 per share and an expiration date of December 28, 2028, and 33,333 shares of common stock issuable upon exercise of options to purchase shares of common stock at an exercise price of $16.50 per share and an expiration date of August 31, 2027, which have vested, or which vest, within 60 days of April 10, 2025. (13) Percentage is based on 8,268,240 shares of Common Stock outstanding as of April 10, 2025, as confirmed by the Issuer's transfer agent on such date. 0001974475 N The Tiger Cub Trust a OO N TX 0.00 605000.00 0.00 605000.00 605000.00 N 7.3 OO (13) Percentage is based on 8,268,240 shares of Common Stock outstanding as of April 10, 2025, as confirmed by the Issuer's transfer agent on such date. Common Stock, $0.0001 par value per share MANGOCEUTICALS, INC. 15110 DALLAS PKWY, SUITE 600 Dallas TX 75248 This Amendment No. 4 (the "Amendment") amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "Commission") on May 3, 2023, as amended by Amendment No.1 thereto filed with the Commission on January 2, 2024 and Amendment No. 2 thereto filed with the Commission on June 5, 2024 and Amendment No. 3 thereto filed with the Commission on August 27, 2024, by Jacob D. Cohen and The Tiger Cub Trust (the Schedule 13D as amended and modified to date, the "Schedule 13D"). Capitalized terms used but not otherwise defined in this Amendment have the meanings ascribed to such terms in the Schedule 13D. Except as expressly amended and supplemented by this Amendment, the Schedule 13D is not amended or supplemented in any respect, and the disclosures set forth in the Schedule 13D, other than as amended herein are incorporated by reference herein. As used in this Amendment: "Common Stock" means the common stock of the Issuer; "Issuer" or "Company" means Mangoceuticals, Inc.; and "Reporting Persons" means Jacob D. Cohen and The Tiger Cub Trust. Effective on October 16, 2024, the Company affected a 1-for-15 reverse stock split of its outstanding common stock, which has been reflected in the disclosures throughout this Amendment. Item 3 is hereby amended and modified to include the following (which shall be in addition to the information previously included in the Schedule 13D): Effective on April 10, 2025, the Company issued, after recommendation by the Compensation Committee of the Company's Board of Directors and approval by the Board of Directors, an aggregate of 200,000 fully-vested and earned shares of Company common stock under the Company's Second Amended and Restated Mangoceuticals, Inc. 2022 Equity Plan (the "Plan"), as a discretionary bonus for consideration for services rendered during 2025 to Mr. Cohen. The aggregate number and percentage of the class of securities beneficially owned by each Reporting Person are set forth on rows 11 and 13 of the cover pages of this Schedule 13D and are incorporated herein by this reference thereto. The aggregate number of shares of Common Stock beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares as to which there is sole power to vote or to direct the voting thereof, shared power to vote or to direct the voting thereof, sole power to dispose or to direct the disposition thereof, or shared power to dispose or to direct the disposition thereof, are set forth on rows 7 through 11 of the cover pages of this Schedule 13D and are incorporated herein by this reference thereto. The information in Item 3 is incorporated by reference into this Item 5(c). No other person has the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of the securities beneficially owned by the Reporting Persons. N/A. Jacob D. Cohen /s/ Jacob D. Cohen Jacob D. Cohen 04/11/2025 The Tiger Cub Trust /s/ Jacob D. Cohen Jacob D. Cohen Trustee 04/11/2025